Prosecution Insights
Last updated: October 23, 2026
Application No. 18/842,194

A PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILE

Final Rejection §DOUBLEPATENT
Filed
Aug 28, 2024
Priority
Mar 07, 2022 — provisional 63/317,187 +1 more
Examiner
RAHMANI, NILOOFAR
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Amgen Inc.
OA Round
2 (Final)
78%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
889 granted / 1146 resolved
+17.6% vs TC avg
Minimal -3% lift
Without
With
+-2.9%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 11m
Avg Prosecution
56 currently pending
Career history
1179
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
14.1%
-25.9% vs TC avg
§102
27.5%
-12.5% vs TC avg
§112
39.0%
-1.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1146 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION 1. Claims 1-2, 4-6, 8-9, 13, 19, 22, 26, 32-33, 36, 39, 45, 47, 54-56, 58, 60, 63-64, 68-71 are pending in the instant application. 2. The rejection of claims 1-2, 4-6, 8-9, 13, 19, 22, 26, 32-33, 36, 39, 45, 47, 54-56, 58, 60, 63-64, 68-71 under obvious type double patenting is maintained for reason of record. Applicants add a solvent and in the presence of FeCl3 and a secondary amine organocatalyst to overcome the rejection. It is examiner’s position that Merely modifying the process conditions such as catalyst and concentration is not a patentable modification absent a showing of unexpected results. In re Aller, 220 F.2d 454, 105 USPQ 233 (CCPA 1955). As such, even though the weight percent of the organic solvent in Example 2 is 15.8% (it states 1200 mL of methanol and 400 mL of water), it would have been obvious for Applicants to slightly change the weight percent of the solvent of the reference and arrive at the instant invention. Changing one catalyst to another is obvious to the skill in art. THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicants are reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for replying to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. 3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /NILOOFAR RAHMANI/ Primary Examiner, Art Unit 1691 10/01/2026
Read full office action

Prosecution Timeline

Aug 28, 2024
Application Filed
Jun 22, 2026
Non-Final Rejection mailed — §DOUBLEPATENT
Sep 21, 2026
Response Filed
Oct 05, 2026
Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758529
USE OF EDARAVONE IN TREATMENT OF AUTISM SPECTRUM DISORDER
2y 5m to grant Granted Oct 13, 2026
Patent 12758538
Crystalline Forms of Apalutamide
2y 4m to grant Granted Oct 13, 2026
Patent 12753181
COMPOUNDS FOR DEGRADATION OF CYCLIN-DEPENDENT KINASE 7(CDK7)
2y 10m to grant Granted Oct 06, 2026
Patent 12735419
PROCESS FOR RACEMIZING AND ISOLATING ATROPISOMERS OF 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE
3y 5m to grant Granted Sep 15, 2026
Patent 12734153
METHODS FOR AMELIORATING AND PREVENTING AGE-RELATED MUSCLE DEGENERATION
2y 10m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
78%
Grant Probability
75%
With Interview (-2.9%)
1y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1146 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month